Severe Covid-19 Cases And Plasma Treatment – What You Need To Know

Severe Covid-19 Cases And Plasma Treatment – What You Need To Know

There are various viable treatments for the Covid-19 disease underway, and one of them is the treatment with plasma. According to the latest reports coming from Reuters, it seems that plasma treatment is actually showing no benefit in the case of severe Covid-19 cases. 

It’s been just reported that blood plasma from Covid-19 survivors has little benefit for patients with severe Covid-19 pneumonia, according to the Argentina researchers who reported the results in The New England Journal of Medicine. 

The so-called convalescent plasma which delivers Covid-19 survivors’ antibodies to the infected patients basically did not improve the ill patients’ health status, or reduce their risk of dying from the disease any better than a placebo.

Reuters notes that “Researchers randomly assigned 333 hospitalized patients with severe COVID-19 pneumonia to receive convalescent plasma or a placebo.”

According to the same official notes, “After 30 days, they saw no significant differences in patients’ symptoms or health. Mortality rates were nearly the same: 11% in the convalescent plasma group and 11.4% in the placebo group, a difference not deemed statistically significant.”

On the other hand, it’s essential to note the fact that plasma treatment might still work for people who don’t have too severe symptoms and it can prevent becoming too ill, according to the official reports. We suggest that you check out more details in the official studies. 

Coronavirus in the news

Apart from all kinds of new treatments for the new disease, there’s also been a lot of talk about the viable vaccines which are currently in testing. 

We recently revealed that Bill Gates made headlines when he recently dropped a gloomy prediction about the future, and he also explained his vaccine-related worries to people. 

Another interesting issue that we just addressed the other day is the fact that AstraZeneca and the University of Oxford’s coronavirus vaccine’s high efficiency may have been due to a dosing error according to the latest reports. 


Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.